(Praluent, manufactured by Sanofi and Regeneron, is Repatha's only current competitor in the PCSK9 inhibitor category.) In sharp contrast, the corresponding disclosure authorization for Praluent copay program is much less burdensome. I understand that I may revoke my permission at any time. By checking this box, I give my permission to use my personal information to receive product and disease-state information from Amgen, its affiliates, service providers, and co-promotion partners. I further understand that if a Health Care Provider is disclosing my personal health information on an on-going basis to Amgen, this Authorization only permits Health Care Providers to do so for 1 year once I sign it or a shorter time period if required by state law. There is no guarantee that my personal health information received by Amgen from a Health Care Provider might not be released to a third party. I understand that where a Health Care Provider discloses my personal health information to Amgen for the purposes contained in this Notice and Authorization, the personal health information disclosed may not be covered by any federal law relating to the use of my personal health information or how it is disclosed. Information Received from Health Care Providers Further, the company specifically warns that there is nothing to prevent it from sharing your information with third parties: The agreement specifically states that by agreeing to the terms patients may lose federal HIPAA protection. But patients can't register for the program without first authorizing Amgen to use their personal information, as the web site makes clear: The most important feature of the program is a copay card which gives patients access to the drug for only $5 a month, but the program also includes reminder emails and a free needle-disposal container. The Repatha copay program is part of the larger RepathaReady program which supplies "support services to help you start and stay on Repatha." She is also a member of the editorial board of Circulation: Cardiovascular Quality and Outcomes. I suggest the policy be revised so that patients in financial need can receive assistance without having to agree to such a wholesale waiver of their privacy rights," said Marilyn Mann, a respected patient advocate who has family members who have familial hypercholesterolemia. "The Amgen privacy policy is much broader than is necessary to achieve the purposes of the copay program and requires, among other things, that patients consent to disclosure of their medical records to unnamed third parties, with no assurances that the information will be kept confidential.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |